Zarrabian Saiid 4
4 · DelMar Pharmaceuticals, Inc. · Filed Nov 16, 2017
Insider Transaction Report
Form 4
Zarrabian Saiid
DirectorInterim CEO
Transactions
- Purchase
Common Stock
2017-11-14$0.82/sh+55,000$45,100→ 55,000 total - Purchase
Common Stock
2017-11-14$0.84/sh+5,900$4,956→ 5,900 total(indirect: By Children)
Footnotes (2)
- [F1]This transaction was executed in multiple trades at prices ranging from $0.8015 to $0.8385. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $0.8298 to $0.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.